无需港股通，A股账户就能T+0买港股>> 港股医药股震荡上升，泰格医药（300347）涨超7%，凯莱英（002821）、康龙化成（300759）均涨近 6%，昭衍新药（603127）涨超5.5%，药明生物涨超4%。 ...

2025.06. 09 本文字数：2444，阅读时长大约4分钟 作者 | 第一 财经 王方然 创新药板块再度走强。6月9日，常山药业（300255.SZ）、舒泰神（300204.SZ）、睿智医药 （300149.SZ）、众生药业（002317.SZ）等多只A股涨停。港股的金斯瑞生物科技 （01548.HK）、四环医药（00460.HK）、诺诚健华（09969.HK）等大涨超10%。 记者注意到，这轮"吃药"行情与过往不同，涨幅龙头集中于创新药企业，且港股表现尤为强劲。 爆发并非偶然，而是政策、业绩与资金面多重因素共振的结果。不过，也有机构认为火热行情下暗藏 波动风险，提醒港股短期或面临获利回吐压力。 截至当日收盘，恒生创新药ETF（159316）、港股通医药ETF（513200）分别上涨4.08%、 4.25%。多只个股涨幅较大。当日盘中，三生制药（01530.HK）股价一度涨超10%，最高触及 22.5港元，距离7年前22.631港元的历史高点仅一步之遥。自今年2月以来，三生制药股价从6港元 的位置一路暴涨，涨幅超过260%。金斯瑞生物科技、四环医药、诺诚健华等涨超10%，信达生物 （01801.HK）、康 ...

Core Viewpoint - The current "medication" market rally is distinct from previous ones, with leading gains concentrated in innovative pharmaceutical companies, particularly strong performance in the Hong Kong stock market [1][2] Group 1: Market Performance - On June 9, both Hong Kong and A-share innovative pharmaceutical sectors saw significant gains, with the Hang Seng Innovative Drug ETF rising by 4.08% and the Hong Kong Stock Connect Medical ETF increasing by 4.25% [3] - Notable individual stock performances included 3SBio (01530.HK) reaching a peak of 22.5 HKD, just shy of its historical high, and a 260% increase in its stock price since February [3] - The A-share innovative drug index rose by 31.5% and the Hong Kong innovative drug index surged by 61.54% since April 9, with several stocks doubling in value [4] Group 2: Catalysts for Growth - The surge in innovative drug stocks is attributed to multiple factors, including recent approvals for 11 innovative drugs from eight companies and promising clinical data for major diseases [5] - The upcoming 2025 ASCO annual meeting will feature 73 research studies from China, a 30% increase from the previous year [5] Group 3: Long-term Positive Factors - Many leading companies are approaching breakeven points, with significant revenue growth reported, particularly for Ascentage Pharma (332.31% growth) [7][8] - The overseas licensing deals have seen substantial increases, with a record-breaking deal of 6.05 billion USD for 3SBio's drug rights to Pfizer [9] - The overall licensing-out transactions in the innovative drug sector have surged, with 41 transactions in Q1 2024 alone, totaling 36.93 billion USD [9] Group 4: Policy Support - Recent policy changes are favorable for innovative drug companies, including optimized centralized procurement policies and increased support for innovative drugs in government reports [10] - The 2024 government work report includes 38 new innovative drugs in the medical insurance catalog, the highest ever, with plans for further optimization in 2025 [10] Group 5: Market Outlook - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, with a current TTM P/E ratio of 27.1 times [11] - Some analysts suggest that the innovative drug sector is transitioning from following to leading in the global market, indicating a new era for domestic innovation [11] - However, there are concerns about potential short-term volatility due to rapid price increases and profit-taking by investors [11]

Market Performance - The Shanghai Composite Index rose by 0.43% to 3399.77 points, marking a five-day consecutive increase [1] - The Shenzhen Component Index increased by 0.65% to 10250.14 points, while the ChiNext Index gained 1.07% to 2061.29 points [1] - Total trading volume in the two markets reached 1.29 trillion yuan, exceeding 1 trillion yuan for eight consecutive days [1] Industry Highlights - The entertainment products sector saw a significant increase of 4.93%, followed by commercial vehicles and chemical pharmaceuticals, which rose by 3.73% and 3.70% respectively [1] - A total of 968 non-currency ETFs rose, with an increase ratio of 84% [1] ETF Performance - The CSI Hong Kong Innovation Drug Index increased by 5.39%, with various related ETFs also showing strong performance, such as the Hong Kong Innovation Drug ETF and the Hong Kong Innovation Drug 50 ETF, which rose by 4.65% and 4.56% respectively [1] - The latest share size of the Hong Kong Innovation Drug ETF reached 9.157 billion shares, closely tracking the CSI Hong Kong Innovation Drug RMB Index [3] - The latest P/E ratio (PE-TTM) for the CSI Hong Kong Innovation Drug Index is 29.28, which is lower than 16.54% of the time over the past three years [4][6] Sector Valuation - The Hang Seng Medical ETF has a latest share size of 1.664 billion shares, tracking the Hang Seng Hong Kong Stock Connect Medical Care Index, which reflects the performance of Hong Kong-listed companies in pharmaceuticals and biotechnology [4] - The latest P/E ratio for the Hang Seng Hong Kong Stock Connect Medical Care Index is 32.30, below 32.20% of the time over the past three years [5] Market Trends - A total of 123 non-currency ETFs declined, with a decrease ratio of 11% [7] - The gold industry theme index saw the largest decline, dropping by 1.11% [7]

Market Overview - The Hong Kong stock market showed a positive trend with the Hang Seng Index rising 1.63% to close at 24,181.43 points, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index also saw significant gains of 1.74% and 2.78% respectively, marking a technical bull market as they rose over 20% from April lows [1] - The trading volume for the day reached 245.83 billion HKD, indicating strong market activity [1] Blue Chip Performance - Kuaishou-W (01024) led the blue-chip stocks with a 5.58% increase, closing at 62.4 HKD, contributing 16.34 points to the Hang Seng Index [2] - Other notable performers included WuXi Biologics (02269) up 5.48%, SMIC (00981) up 5.1%, while Budweiser APAC (01876) and Zijin Mining (02899) experienced declines of 2.06% and 1.64% respectively [2] Sector Highlights - Major technology stocks collectively rose, with Kuaishou increasing over 5% and Meituan and JD.com both rising over 4% [3] - The innovative drug sector showed strong performance, with stocks like Eucure Biopharma-B (01477) up 19.45% and King’s Ray Biotech (01548) up 16.14% [3][4] - The Chinese securities sector saw a broad increase, with firms like Everbright Securities (06178) rising 5.27% and GF Securities (01776) up 4.66% [4] Regulatory Developments - The China Securities Regulatory Commission approved the transfer of control for eight companies to Central Huijin, which may lead to a new wave of mergers and acquisitions in the securities industry [5] Consumer and Technology Trends - The upcoming Apple Worldwide Developers Conference (WWDC 2025) is expected to drive interest in consumer electronics and related stocks, with companies like AAC Technologies (01415) and Sunny Optical (02382) showing gains [6] - New consumption stocks also performed well, with companies like Bruker (00325) rising 22.34% [6][7] Commodity Movements - Gold stocks faced declines, with Shandong Gold (01787) down 3.99%, influenced by stable U.S. employment data which suggests the Federal Reserve may maintain its current interest rate stance [7] Notable Stock Movements - China Rare Earth (00769) surged 60% following news of eased export controls on rare earths, reflecting strong market interest [8] - Huicai Holdings (01180) experienced a dramatic drop of 47.54% before being suspended, indicating volatility in the entertainment equipment sector [9]

Group 1 - The Hang Seng Index (HSI) Hong Kong Stock Connect Index showed active performance with a rise of 0.84% as of 1:39 PM [1] - The newly listed N Hong Kong Stock Connect Hang Seng ETF (520940) had a trading volume of 133 million yuan on its first day, with a turnover rate of 22.24% [1] - Major stocks in the ETF, such as Kuaishou-W, Meituan-W, WuXi Biologics, and ZTO Express-W, experienced significant gains, with Kuaishou-W rising over 5% [1] Group 2 - Southbound capital has been actively buying Hong Kong stocks, with net inflows exceeding 660 billion HKD as of June 6, significantly higher than the same period last year [1] - The annual Worldwide Developers Conference (WWDC) by Apple is scheduled from June 10 to 14, showcasing innovations across various operating systems [1] Group 3 - Cathay Securities reported that the AI industry cycle may lead the Hong Kong stock market upward amid the transition of old and new driving forces [2] - The influx of southbound capital is strengthening pricing power, indicating potential for further growth in the Hong Kong market [2] - The Hang Seng Index's price-to-earnings (PE) ratio has increased from approximately 7.5 times to 10.5 times, aligning with the ten-year average, suggesting room for further appreciation compared to previous highs [2]

Core Viewpoint - The pharmaceutical sector, particularly innovative drugs, experienced a significant surge on June 9, with related ETFs in the Hong Kong market rising collectively by over 4% in half a day, indicating high trading activity and investor interest [1]. Group 1: ETF Performance - The Hong Kong innovative drug ETFs saw substantial gains, with the following notable performances: - Guotai Innovative Drug ETF (517110) increased by 4.7%, with a trading volume of 814.38 million yuan and a scale of 4.29 million units [2][3]. - Hong Kong Innovative Drug ETF Fund (520700) rose by 4.65%, with a trading volume of 4.32 billion yuan and a scale of 2.18 million units [5]. - Hong Kong Innovative Drug 50 ETF (513780) gained 4.63%, with a scale of 4.2 million units [5]. - Hong Kong Innovative Drug ETF (513120) increased by 4.44%, with a trading volume of 49.82 billion yuan and a scale of 91.57 million units [6]. Group 2: Investment Logic - The investment logic for innovative drugs is driven by both domestic and international factors: - Domestic policies, such as the "腾笼换鸟" (Tenglong Huanniao) policy, are creating more payment space for innovative drugs, facilitating the import substitution process and providing better service and policy support for domestic innovative drugs [2]. - A significant number of innovative drug companies are expected to reach profitability this year, as high R&D investments begin to translate into revenue growth, leading to profit elasticity [2]. Group 3: Market Dynamics - Prior to Q3 2022, innovative drugs were largely overlooked by the market, with minimal research and trading activity, resulting in a bottoming out of asset prices and industry cycles [3]. - It is anticipated that innovative drugs will become a standard allocation for active pharmaceutical fund managers in the next two years, potentially attracting an additional 30-50 billion yuan in investment, while the current circulating market cap for innovative drugs is around 30 billion yuan [3]. Group 4: Index Composition - The CSI Hong Kong Innovative Drug Industry Index selects up to 50 publicly listed companies involved in innovative drug R&D in the Hong Kong market, reflecting the overall performance of these companies [7]. - Major weighted stocks in the index include: - BeiGene (6160.HK) with a weight of 11.99% - Heng Rui Medicine (600276) with a weight of 9.35% - WuXi AppTec (603259) with a weight of 9.31% [4][8].

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug stocks, particularly in the Hong Kong market, with significant gains in related ETFs and a notable increase in capital inflow [1][2] - The Hong Kong Innovative Drug 50 ETF (513780) saw a 5.14% increase in early trading on June 9, with a transaction volume exceeding 336 million yuan, and several component stocks, including King’s Ray Biotechnology, rising over 15% [1] - The innovative drug sector has shown remarkable performance this year, with many related ETFs increasing by over 50%, indicating a robust independent market trend despite broader market fluctuations [1] Group 2 - According to Huafu Securities, the total transaction amount for innovative drug BD is projected to rise from 9.2 billion USD in 2020 to 52.3 billion USD by 2024, with upfront payments increasing from 600 million USD to 4.1 billion USD [1] - The China Securities Index indicates that the top ten component stocks of the Hong Kong Innovative Drug Index account for 71.5% of the total weight, including high-quality A-share companies like Innovent Biologics and BeiGene [2] - The ETF supports T+0 trading, allowing investors to conduct multiple transactions within a trading day, enhancing capital efficiency and liquidity [2]

Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 17.71% and a transaction volume of 46.90 million yuan, indicating a vibrant market activity [3] - Over the past six months, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 51.07 million yuan, ranking first among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 26.52, which is in the 8th percentile over the past three years, indicating a historical low valuation [3] Group 2 - As of May 29, the number of globally approved new drugs in China has reached 54, with 34 being domestic innovative drugs and 20 imported, showing a strong growth in domestic innovation [3] - The approval of domestic innovative drugs in 2024 is projected to be 37, while the number approved in the first half of this year is close to last year's total, highlighting a rapid increase in innovation [3] - Institutions believe that the competitiveness of domestic innovative drugs in the global market is rising, and international investors are increasingly confident in Chinese innovative pharmaceutical companies [4]

6月9日周一，A股高开，三大股指集体上涨，沪指重返3400点，生物医药、券商等板块活跃。港股高开高走，恒 指、恒科指双双涨超1%，科技股走强，新消费三宝分化，蜜雪集团大涨9%，老铺黄金跌超1%。债市方面，国债期 货多上涨。核心市场走势： | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 400 | 3398.20 | 12.84 | 0.38% | | 399001 | 深证成指 | | 10269.89 | 86.20 | 0.85% | | 399006 | 创业板指 | | 2073.05 | 33.61 | 1.65% | | 000300 | 沪深300 | | 3889.16 | 15.18 | 0.39% | | 000016 | FIFFS0 | | 2691.23 | 2.38 | 0.09% | | 000680 | 科创综指 | | 1207.84 | 16.45 | 1.38% | | 000688 | 科创20 | | 998.48 | 6.84 | 0. ...